WeDoctor and GenSci Pharma Forge Strategic Alliance to Advance the 'Women and Children Health Navigation Initiative'

On September 22, WeDoctor Group and GeneScience Pharmaceuticals signed a letter of intent for strategic cooperation on the “Women’s and Children’s Health Protection Plan.” The two parties will leverage their respective resource advantages to jointly build a digital health service system for women and children, systematically advance the development of the “Women’s and Children’s Health Protection Service Platform,” and collaboratively develop supporting products and services for the plan, thereby exploring new models of healthcare services for women and children.

WeDoctor Group and GeneScience Pharmaceuticals Sign Letter of Intent for Strategic Cooperation

Jing Weiguo, Executive Vice President and Chief Operating Officer of WeDoctor Group, and Hu Weijun, General Manager of the Pediatric Business Group at GeneScience Pharmaceuticals, signed a framework letter of intent for cooperation on behalf of their respective parties. Zhang Xiaochun, Co-founder and Vice Chairman of WeDoctor Group, Vice President Li Bing, and Dou Zhiguo, General Manager of Domestic Marketing at GeneScience Pharmaceuticals, attended the signing ceremony and engaged in in-depth discussions on the diversified cooperative businesses between the two sides.

As planned, the two parties will leverage WeDoctor’s strengths in digital healthcare services and channel deployment, along with GeneScience Pharmaceuticals’ advantages in high-quality products and distribution channels within the women’s and children’s health sectors. By integrating resources from authoritative experts and pharmaceutical industry partners, they will initiate efforts in public science education and the development of digital service platforms focused on pediatric growth and development, as well as women’s and reproductive health. Together, they will drive the implementation of initiatives such as public science education for women and children and the construction of specialized digital healthcare services.

It is reported that prior to reaching a strategic cooperation intent, WeDoctor Group and GeneScience Pharmaceuticals had engaged in multiple rounds of discussions on diversified collaboration models between digital healthcare platforms and traditional pharmaceutical companies. The high degree of alignment between the two parties in their layout of women’s and children’s health service systems has provided a favorable opportunity for launching this strategic partnership.

JinSai Pharmaceutical Delegation Visits WeDoctor Group for Exchange

As China’s largest digital healthcare service platform, WeDoctor Group is committed to driving progress through technology and innovation. It empowers all stakeholders across the healthcare value chain—including healthcare providers, payers, and supply chain partners—to achieve deep integration of online and offline medical resources. The company provides users with integrated online-offline healthcare and health management services across multiple scenarios, thereby enhancing the accessibility, effectiveness, and affordability of medical care while promoting the continuous improvement of overall efficiency in China’s healthcare system.

As of the end of 2020, WeDoctor operated 27 internet hospitals, 17 of which were designated as medical insurance providers. Meanwhile, the WeDoctor platform connected more than 7,800 hospitals, covering over 95% of China’s Grade A tertiary hospitals, and included more than 270,000 registered physicians, 86% of whom were attending physicians or above. Leveraging its platform resources, WeDoctor has continuously innovated service models for women’s and children’s health to enhance the quality of care in this sector.

“This collaboration encompasses not only the development of a digital service platform for women’s and children’s health, but also extends to multiple professional domains where our respective strengths are complementary, including patient education, channel integration, digital specialty development, and innovation in medical services…” At the symposium, Zhang Xiaochun stated that the strategic alliance between WeDoctor Group and GeneScience Pharmaceuticals will not only open up broader development prospects for both parties, but also serve as an innovative model for diversified business cooperation between digital healthcare platforms and traditional pharmaceutical companies.

As a company dedicated to improving human life and health through technology, GeneScience Pharmaceuticals remains committed to providing physicians and patients with optimal products and solutions. Focusing on areas such as pediatric growth and development—including height, obesity, sexual development, neuropsychiatric development, and pediatric autoimmune diseases—the company leverages cutting-edge technologies to develop innovative products, including medical devices and healthcare data solutions, thereby establishing comprehensive solutions spanning early screening, monitoring, intervention, and treatment. Meanwhile, GeneScience Pharmaceuticals is also actively exploring fields such as women’s health, anti-aging, and oncology, striving to ensure the healthy growth of Chinese children and enable all individuals to age in good health and happiness.

“This strategic partnership represents both the culmination of our previous explorations into diversified collaboration and the starting point for deeper, broader cooperation between the two parties,” stated Dou Zhiguo at the seminar. He noted that with maternal and child health services as the focal point for joint efforts, GenSci Pharmaceutical and WeDoctor Group will further deepen and implement their diversified collaboration, expressing hope that digital healthcare service platforms will create new business growth drivers for traditional pharmaceutical companies.